Pfizer Partnership Ready to Flourish; Opko Health Brief Report Issued by BrokerBank Securities, Inc.

NEW YORK, April 22, 2015 /PRNewswire/ -- Opko Health, Inc. (NYSEMKT: OPK) a Miami based multi-national pharmaceutical and diagnostics company announced today the publication of a study entitled 'Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study'. The study shows that the four kallikrein panel of biomarkers utilized in the OPKO 4Kscore Test (Total PSA, Free PSA, Intact PSA and hK2) accurately identifies risk for aggressive prostate cancer prior to prostate biopsy.

The Prostate Testing for Cancer and Treatment (ProtecT) study is a prospective randomized controlled trial conducted in the United Kingdom for the purpose of evaluating the cost effectiveness of conventional treatments in PSA-detected, clinically localized prostate cancer. Of the 82,428 men recruited for the trial, a total of 6129 men with elevated PSA (=3.0 ng/mL) who underwent prostate biopsy and provided an adequate blood sample were tested for the four kallikreins and their 4Kscore result was determined. The study showed that the four kallikrein panel enhanced aggressive prostate cancer detection compared with PSA and age alone. The area under the curve for the 4K model was 0.820 (95% CI = 0.802 to 0.838) while the PSA model was 0.738 (95% CI = 0.716 to 0.761) for high-grade cancer.

For a more detailed research report with analyst comments and recommendation on Opko Health, Inc. please follow the link. There is no cost obligation required to view analyst brief.

http://bit.ly/-OPK-AnalystReport

Copy and paste to browser may be required.

This report was prepared for informational purposes only.  Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company.  A full disclaimer can be found by viewing the full analyst report.

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.  

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Robert Borowski, research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.

Related Links

http://www.brokerbanksecurities.com